Related News、 Thrombosis Adviser、抗血栓療法トライアルデータベース、3つの サイトより、AF治療や抗血栓療法に関する論文や記事、トライアルを紹介いたします。 新しい話題について、随時更新してまいります。

Thirugnanam S, Pinto R, Cook DJ, Geerts WH, Fowler RA.
Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review.
Crit Care 2012 Mar 9;16(2):R43. [Epub ahead of print]
Ageno W, Spyropoulos AC, Turpie AG.
Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.
Thromb Haemost 2012 May 31;107(6):1027-1034
Bassand JP.
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.
Europace 2012 Mar;14(3):312-324
Cohen AT, Dobromirski M.
The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Thromb Haemost 2012 May 31;107(6):1035-1043
Duggan ST.
Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Am J Cardiovasc Drugs 2012 Feb 1;12(1):57-72
Morales-Vidal S, Schneck MJ, Flaster M, Biller J.
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Expert Rev Neurother 2012 Feb;12(2):179-190
Patel PA, Ramakrishna H, Andritsos M, Wyckoff T, Riha H, Augoustides JG.
The year in cardiothoracic and vascular anesthesia: selected highlights from 2011.
J Cardiothorac Vasc Anesth 2012 Feb;26(1):3-10
Schulman S, Crowther MA.
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.
Blood 2012 Mar 29;119(13):3016-3023
Tendera M, Syzdl M, Parma Z.
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Cardiol J 2012;19(1):4-10
Wiggins NB, Granger CB, Alexander JH.
Novel Oral Anticoagulants After Acute Coronary Syndromes.
Cardiovasc Drugs Ther 2012 Jun;26(3):265-271
EINSTEIN-PE Investigators, Bller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A.
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
N Engl J Med 2012 Apr 5;366(14):1287-1297
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators.
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
N Engl J Med 2012 Jan 5;366(1):9-19
Roe MT, Ohman EM.
A New Era in Secondary Prevention after Acute Coronary Syndrome
N Engl J Med 2012 Jan 5;366(1):85-87
The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators.
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study.
Am Heart J 2010;159(3):340-347
Samama MM, Martinoli JL, Leflem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
Assessment of laboratory assays to measure rivaroxaban an oral, direct factor Xa inhibitor.
Thromb Haemost 2010;103.
Kubitza D, MueckW, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67-77
Kubitza D, Mueck W, Becka M
No interaction between rivaroxaban - a novel, oral, direct Factor Xa inhibitor- and atorvastatin.
Expert Opinion On Pharmacotherapy Pathophysiol Haemost Thromb 2007/2008;36:A40
Perzborn E, Buetehorn U, Fischer E, Harwardt M, Klages M, Trabandt A.
Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran , but is reduced by the direct factor Xa inhibitor rivaroxaban
Eur Heart J 2008;29(Abstract Supplement):825
Perzborn E, Harwardt M.
Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin-Thrombomodulin-Protein C System
Blood (ASH Annual Meeting Abstracts) 2008;112:528
Turpie AGG
New oral anticoagulants in atrial fibrillation.
Eur Heart J 2008;29(2):155-165
Turpie AGG
Warfarin replacements: mechanisms underlying emerging agents
Can J Cardiol 2008;24:56-60
Varin R, Mirshahi S, Mirshahi P, Lu-Hong L, Kierzek G, Vigneau JF, Marie J-P, Perzborn E, Mirshahi M, Soria C, Soria J.
Improvement of Thrombolysis by Rivaroxaban, an Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis
Blood (ASH Annual Meeting Abstracts) 2008;112:3031
Halabi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Schafers R, Wand D, Philipp T, Bruck H
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor.
Blood 2006;108:Abstract 913
Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin.
Eur Heart J 2007;28(Suppl. 1):189
Kubitza D, Becka M, Mueck W, Zuehlsdorf M
The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral direct Factor Xa inhibitor.
Blood 2006;108:Abstract 905
Kubitza D, Becka M, Zuehlsdorf M, Mueck W
No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin
J Clin Pharmacol 2006; 46(6):702